Find disease awareness content and relevant supporting materials
OPTIC Phase III trial of Tepezza shows benefits in less severe Thyroid Eye Disease.- Horizon Therapeutics
Horizon Therapeutics announced new Tepezza (teprotumumab-trbw) study data, including findings suggesting benefits of Tepezza in the less severe eye of patients with Thyroid Eye Disease (TED), and new data from the OPTIC 48-week follow-up study and OPTIC-X clinical trial. In patients with TED, one eye can have more severe symptoms than the other.
Latanoprost 50 Micrograms/ml eye drops, solution
Reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma and ocular hypertension in adults (including the elderly). Reduction of elevated IOP in paediatric patients with elevated IOP and paediatric glaucoma.
Brinzolamide 10mg/ml eye drops suspension
Brinzolamide is indicated to decrease elevated intraocular pressure in: • ocular hypertension • open-angle glaucoma as monotherapy in adult patients unresponsive to beta-blockers or in adult patients in whom beta-blockers are contraindicated or as adjunctive therapy to beta-blockers or prostaglandin analogues (see also section 5.1).